| Aktie | Ticker | Breite | GCS | 2025/Q3 | |||
|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 81.319.135 $ | +29.420.084 $ | +83,6 % | 3 | ||||
| Beam Therapeutics Inc. | BEAM | → 0 | Neutral | 55.018.488 $ | +16.457.941 $ | +42,7 % | 1 |
| Lyell Immunopharma, Inc. | LYEL | → 0 | Neutral | 16.371.804 $ | +7.460.059 $ | +83,7 % | 1 |
| Prime Medicine, Inc. | PRME | → 0 | Schwach | 9.928.843 $ | +5.502.084 $ | +124,3 % | 1 |
| 81.319.135 $ | +29.420.084 $ | +83,6 % | 3 | ||||